R. Morphy

发表

Selectively nonselective kinase inhibition: striking the right balance.

R. Morphy, 2010, Journal of medicinal chemistry.

Design of Multitarget Ligands

R. Morphy, Z. Rankovic, 2010 .

Medicinal Chemistry Approaches for Multitarget Drugs

R. Morphy, Z. Rankovic, 2010 .

Designed multiple ligands. An emerging drug discovery paradigm.

R. Morphy, Z. Rankovic, 2005, Journal of medicinal chemistry.

Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists

R. Morphy, J. Tierney, I. Cumming, 2010 .

Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.

J. Mestres, R. Morphy, G. Zaman, 2011, Bioorganic & medicinal chemistry letters.

Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.

R. Morphy, J. de Man, A. Lyons, 2011, Bioorganic & medicinal chemistry letters.

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor

Xiaoen Wang, R. Morphy, A. Moossa, 1997, Clinical & Experimental Metastasis.

Chapter 27 – Multi-target Drugs: Strategies and Challenges for Medicinal Chemists

R. Morphy, Z. Rankovic, 2008 .

Chapter 19 – Multitarget Drugs: Strategies and Challenges for Medicinal Chemists

R. Morphy, Z. Rankovic, 2008 .

From magic bullets to designed multiple ligands.

Richard Morphy, Corinne Kay, Zoran Rankovic, 2004, Drug discovery today.

Fragments, network biology and designing multiple ligands.

Richard Morphy, R. Morphy, Z. Rankovic, 2007, Drug discovery today.

The physicochemical challenges of designing multiple ligands.

Richard Morphy, R. Morphy, Z. Rankovic, 2006, Journal of medicinal chemistry.

Resin-immobilised benzyl and aryl vinyl sulfones: New versatile traceless linkers for solid-phase organic synthesis

R. Morphy, D. Rees, D. Gani, 1997 .

Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists.

Mark A. Weston, R. Morphy, G. Wishart, 2005, Bioorganic & medicinal chemistry letters.

Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.

Glenn Walker, James Baker, Richard Morphy, 2010, Bioorganic & medicinal chemistry letters.

CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.

R. Morphy, B. Mason, R. Allen, 2002, Bioorganic & medicinal chemistry letters.

Designed Multiple Ligands. An Emerging Drug Discovery Paradigm

Richard Morphy, R. Morphy, Z. Rankovic, 2006 .

High Throughput Screening Approach to Lead Discovery

Craig Jamieson, Richard Morphy, Zoran Rankovic, 2010 .

Defining Target Engagement Required for Efficacy In Vivo at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt).

G. Durst, D. Clawson, R. Morphy, 2021, Journal of medicinal chemistry.

Designing multiple ligands - medicinal chemistry strategies and challenges.

Richard Morphy, Zoran Rankovic, R. Morphy, 2009, Current pharmaceutical design.

Lead Generation Approaches in Drug Discovery

Richard Morphy, Zoran Rankovic, R. Morphy, 2010 .

Selective Multitargeted Drugs

R. Morphy, 2012 .

The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds.

Richard Morphy, R. Morphy, 2006, Journal of medicinal chemistry.

The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.

R. Morphy, A. Haunsø, D. Buchanan, 2011, Bioorganic & medicinal chemistry letters.

Selectively nonselective kinase inhibition: striking the right balance.

R. Morphy, 2010, Journal of medicinal chemistry.